Anti-CD8 Antibodies for PET Imaging and T Cell Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for diagnostic tools to predict and monitor the suitability or responsiveness of a subject to anti-tumor therapy, particularly in relation to CD8 positive T cell activity, which is crucial for effective treatment outcomes.
Innovation Solution
Development of monoclonal antibodies and antigen-binding fragments that specifically bind to CD8, which can be used to modulate CD8 positive T cell activity, and their application in radiolabeled and fluorescently labeled forms for imaging and therapeutic purposes, including PET imaging to visualize CD8 expression in tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies specifically binding to CD8 are developed, then the ability to target and modulate CD8 positive T cell activity is improved, but the complexity of the therapeutic and diagnostic system increases
Solution Approach 1:
The patent provides antigen-binding fragments (such as Fab, F(ab')2, or scFv) in addition to full-length antibodies, allowing the targeting function to be segmented into smaller functional units that can be used in different therapeutic and diagnostic contexts
Solution Approach 2:
The anti-CD8 antibodies and fragments can be used for multiple purposes including therapeutic modulation of T cell activity, diagnostic imaging via PET, and monitoring treatment response, making a single targeting mechanism serve multiple functions
2Measurement precision
If radiolabeled anti-CD8 antibodies are used for PET imaging, then the ability to visualize CD8 expression in vivo is improved, but the complexity of the imaging and therapeutic system increases
Solution Approach 1:
The patent introduces radiolabeled antibodies as intermediary agents that bridge the gap between the anti-CD8 targeting function and the PET imaging detection system, enabling non-invasive visualization of CD8 expression in living subjects
Solution Approach 2:
The radiolabeled antibodies produce detectable signals through positron emission that can be visualized as changes in signal intensity or 'color' in PET images, allowing quantitative measurement of CD8 expression levels in tissues
3Reliability
If anti-CD8 antibodies are used to modulate T cell activity, then the ability to treat CD8 positive T cell-mediated diseases is improved, but the risk of off-target effects and immunogenicity increases
Solution Approach 1:
The patent specifies different constant regions (e.g., IgG1, IgG4) and isoforms (alpha or beta) that can be selected to optimize the local biological properties and reduce immunogenicity in specific therapeutic contexts
Solution Approach 2:
The patent allows modification of the antibody parameters including isotype, affinity, and epitope specificity to adjust the balance between therapeutic efficacy and reduction of harmful immunogenic responses
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibodies and fragments enable targeted modulation of CD8 positive T cell activity, aiding in the prediction and monitoring of anti-tumor therapy response by visualizing CD8 expression in tissues, thereby improving treatment efficacy and monitoring.
Implementation Method 1
monoclonal antibodies labeled with positron emitters, combining the targeting properties of an antibody with the sensitivity of positron emission tomography cameras
Implementation Method 2
fluorescently labeled anti-CD8 antibodies, and their use in imaging
Data Source
AI summary
Anti-CD8 antibodies, radiolabeled anti-CD8 antibodies, fluorescently labeled anti-CD8 antibodies and their use in imaging are provided herein. Included are methods of detecting the presence of CD8 proteins in a subject or sample.